glp-1 parkinson's disease Signalling as a Therapeutic Avenue in Disease: A Comprehensive Review Beyond insulin: The Intriguing role

Joint pain (arthralgia) is not generally recognised as a common class-wide side effect of GLP-1 receptor agonists, though individual product profiles vary

I joined Ro because I had seen friends living with Type 2 diabetes lose weight, lower their A1c levels, and get a new chance at a healthier, happier life with GLP-1s

van Raalte DH, Bjornstad P, Persson F et al (2019) The impact of sotagliflozin on renal function, albuminuria, blood pressure, and hematocrit in adults with type 1 diabetes

Results of a meta-analysis of clinical studies (21) indicate that treatment with GLP-1 receptor agonists is associated with A1C reductions from baseline of 0.42% for exenatide 5 g BID, 0.50% for lixisenatide 20 g once daily, 0.69% for albiglutide 30 mg QW, 0.71% for liraglutide 1.2 mg once daily, 0.75% for exenatide 10 g BID, 1.03% for liraglutide 1.8 mg once daily, and 1.09% for exenatide 2 mg QW and dulaglutide 1.5 mg QW versus placebo